Kee-Young Shin

Jul 24, 2023 | acsjournals.onlinelibrary.wiley.com | Jonathan Leeman |Kee-Young Shin |Yu-Hui Chen |Raymond Mak

ORIGINAL ARTICLE This work has been accepted for presentation at European Society for Radiotherapy and Oncology 2023 in abstract form. See editorial on pages 000–000, this issue. Abstract Background Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate cancer management but there remain significant toxicity risks when delivering prostate SBRT with standard techniques.